Postmenopausal Bleeding

Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

Postmenopausal bleeding (PMB) is defined for practical purposes as vaginal bleeding occurring after twelve months of amenorrhoea, in a woman of the age where the menopause can be expected.[1]Hence it does not apply to a young woman, who has had amenorrhoea from anorexia nervosa, or a pregnancy followed by lactation. However, it can apply to younger women following premature ovarian failure or premature menopause. Unscheduled bleeding in women of menopausal age taking hormone replacement therapy (HRT) should be managed in the same way from a practical perspective.[2] 'Unscheduled bleeding' is defined as non-cyclical bleeding still continuing six months after commencing HRT or after six months of amenorrhoea.

Although PMB usually has a benign cause, the priority is to exclude malignancy.

Postmenopausal bleeding is a common problem representing 5% of all gynaecology outpatient attendances.[3] These are most commonly to eliminate endometrial cancer as the cause of the bleed.

Risk factors for endometrial cancer[4, 5]

  • Many risk factors relate to oestrogen exposure.
  • Unopposed oestrogen-only HRT.
  • Tamoxifen use - it has an anti-oestrogen effect on the breast, but a pro-oestrogen effect on the uterus and bones.
  • Low parity or infertility.
  • Early menarche and late menopause.
  • Increasing age.
  • Polycystic ovarian disease.
  • Hereditary non-polyposis colorectal carcinoma.
  • Obesity combined with diabetes.
  • Hypertension.

Protective factors for endometrial cancer[4]

  • Use of combined oral contraceptives decreases risk.
  • Grand multiparity.
  • Cigarette smoking.

History and examination may possibly indicate cause, but it is generally accepted that PMB should be treated as malignant, until proved otherwise. This requires referral to a gynaecologist with an appointment within two weeks.[6]

Transvaginal ultrasound scan (TVUS)

TVUS is an appropriate first-line procedure to identify which women with PMB are at higher risk of endometrial cancer.

The mean endometrial thickness in postmenopausal women is much thinner than in premenopausal women. Thickening of the endometrium may indicate the presence of pathology. In general, the thicker the endometrium, the higher the likelihood of important pathology, ie endometrial cancer being present. The threshold in the UK is 5 mm; a thickness of >5 mm gives 7.3% likelihood of endometrial cancer.[7] In a woman with PMB, if endometrial thickness is less than 5 mm uniformly, the probability of carcinoma is less than 1%.[5] Some pathology may be missed and it is recommended that hysteroscopy and biopsy should be performed if clinical suspicion is high.[8] The accuracy of assessing endometrial thickness in women with diabetes and obesity has been questioned.[9]However, models have been developed to take personal characteristics into account when predicting the risk of cancer.[10]

Endometrial biopsy

A definitive diagnosis in PMB is made by histology. Historically, endometrial samples have been obtained by dilatation and curettage. Nowadays it is more usual to obtain a sample by endometrial biopsy, which can be undertaken using samplers. Endometrial biopsy can be performed as either an outpatient procedure, or under general anaesthetic (GA). All methods of sampling the endometrium will miss some cancers.


Hysteroscopy and biopsy (curettage) are the preferred diagnostic technique to detect polyps and other benign lesions. Hysteroscopy may be performed as an outpatient procedure, although some women will require GA. Where they are available, referral to 'one stop' specialised clinics is ideal.[11] At such clinics several investigations are available to complement clinical evaluation, including ultrasound, endometrial sampling techniques and hysteroscopy. Following such assessment, reassurance can be given or further investigations or treatment can be discussed and arranged.

Where pathology is found it needs to be treated and prognosis will depend upon the condition and, if malignant, the stage. One stop clinics provide a fast and efficient way of investigating PMB.

Most women with PMB will not have significant pathology but the dictum remains that: postmenopausal bleeding is cancer until proved otherwise.

  • PMB in women on HRT still needs investigation.
  • An obvious lesion like atrophic vaginitis does not exclude another lesion.
  • Many women are unable to distinguish between vaginal and urinary bleeding and some are unable to distinguish rectal bleeding. One paper found that, in women presenting with PMB, the prevalence of bladder tumours was 1.07% and of bladder cancer was 0.7%.[12]


Women with breast cancer who take tamoxifen on a long-term basis are at increased risk of endometrial cancer. In view of the increased risk of endometrial cancer associated with tamoxifen therapy, there is a case for heightened vigilance for PMB by both the women and the clinician(s) responsible for their care. Tamoxifen can cause other changes to the endometrium, and ultrasound may be more difficult to interpret. All women with PMB on tamoxifen would normally have hysteroscopy and biopsy in addition to ultrasonography.

Did you find this information useful?

Original Author:
Dr Hayley Willacy
Current Version:
Dr Mary Harding
Peer Reviewer:
Prof Cathy Jackson
Document ID:
2636 (v23)
Last Checked:
18 February 2014
Next Review:
17 February 2019

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.